Pharma Focus Asia

Symbiomix Therapeutics Submits New Drug Application to US FDA for Solosec™

Friday, January 20, 2017

Symbiomix, a biopharmaceutical company bringing innovative medicines to market for prevalent gynecological infections, today announced submission of a new drug application (NDA) for Solosec™ (secnidazole oral granules) for the treatment of bacterial vaginosis (BV) to the US Food and Drug Administration (FDA). Solosec™ is a potent, next-generation, investigational 5-nitroimidazole antibiotic with enhanced pharmacokinetic properties, and is anticipated to be the first and only single-dose oral therapy approved for BV.

"Following decades of little innovation, Solosec™ represents an important potential advancement in the treatment of women's health infections," commented Robert Jacks, President & CFO. "As a single-dose oral treatment, Solosec™ could improve adherence, potentially leading to better health outcomes for the millions of women suffering with BV."

The NDA is supported by data from a comprehensive set of non-clinical and clinical studies conducted by Symbiomix, including the two pivotal trials in BV (SYM-1219-201 and SYM-1219-301) presented at the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meetings in 2015 and 2016, respectively.

Solosec™ has been designated a Qualified Infectious Disease Product (QIDP) by the FDA for the treatment of BV and received Fast Track designation from the agency in 2015, making Solosec™ eligible for Priority Review and at least 10 years of market exclusivity.

Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024